While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our patent strategy in the long run.
All entries for: Oncology
May 12, 2026
C4 Therapeutics, Inc.
Negative Outlook
Watertown, MA
51-200 employees
These changes are expected to reduce overall Medicaid enrollment and access to care. Although the effect on our future product candidates or business is unknown, any decrease in the number of insured patients or reimbursement levels for our products could adversely affect our potential for revenue and our commercial prospects.
Disease Area: Multiple, Neurological Diseases, Oncology
Drug Type: Small Molecule
May 11, 2026
Eikon Therapeutics, Inc.
Negative Outlook
Millbrae, CA
201-500 employees
In any event, the IRA is likely to have a significant impact on the pharmaceutical industry and may reduce the prices we can charge, and the reimbursement we can receive, for our products, among other effects.
Disease Area: Oncology
Drug Type: Small Molecule
May 11, 2026
Sana Biotechnology, Inc.
Negative Outlook
Seattle, Washington
51-200 employees
If we obtain regulatory approval for any of our product candidates, the IRA could substantially and negatively impact the prices we may charge for such products, which could harm our ability to generate revenue and achieve and sustain profitability.
Disease Area: Endocrinology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic
May 8, 2026
Gildead Sciences
Layoffs
Foster City, CA
10,000+ employees
In the wake of closing its $7.8 billion Arcellx acquisition last week, Gilead Sciences is gutting the biotech’s workforce in California and Maryland, laying off 192 employees total. Given Arcellx had 220 employees as of March 1, according to an SEC filing last month, the cuts are likely wiping out 87% of the staff.
The largest cuts are happening at the biotech’s headquarters in Redwood City, California. Gilead is letting go of 108 employees at that site effective June 30, according to a Worker Adjustment and Retraining Notification (WARN) notice. The pharma is also laying off 84 people in Rockville, Maryland. Those cuts are taking place over a longer period, from June 30, 2026, to April 30, 2027, according to a WARN notice.
Both notices were dated April 30, two days after Gilead announced it had completed its acquisition of Arcellx, making the biotech a wholly owned subsidiary.
Disease Area: Antiviral, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
May 8, 2026
Novartis
Layoffs
Basel, Baselstadt
10,000+ employees
Novartis plans to close a production facility in Wehr, Germany, by the end of 2028, a move that’s expected to eliminate 220 jobs, the Swiss pharma announced May 5.
The site, which makes solid oral dosage forms such as tablets and capsules for mostly established Novartis products, is no longer competitive, the company noted in its announcement. Novartis said it remains committed to Germany as a business location.
The pharma is investing 35 million euros (about $41 million) into a new production facility for radioligand therapies in Halle, Germany. The site will produce personalized cancer therapies for patients in Germany and should be operational in 2027, according to the announcement.
Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule